Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (EXAS)
NASDAQ:EXAS
EXAS Stock Chart & Stats
$62.91
-$1.49(-2.61%)
At close: 4:00 PM EST
$62.91
-$1.49(-2.61%)
Day’s Range― - ―
52-Week Range$38.81 - $72.83
Previous CloseN/A
Volume846.89K
Average Volume (3M)2.21M
Market Cap
$11.88B
Enterprise Value$11.72B
Total Cash (Recent Filing)$858.43M
Total Debt (Recent Filing)$2.52B
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Nov 03, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding189,319,100
10 Day Avg. Volume2,061,424
30 Day Avg. Volume2,211,998
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue3.99
Enterprise Value/Gross Profit5.84
Enterprise Value/Ebitda-14.31
Forecast
1Y Price Target
$67.76Price Target Upside7.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
Bulls Say, Bears Say
Bulls Say
Market PotentialThe Cancerguard test represents a largely untapped addressable market of $25 billion, which could provide significant growth opportunities for Exact Sciences.
Product LaunchExact Sciences launched its Multi-Cancer Early Detection (MCED) test, Cancerguard, which addresses approximately 70% of cancers lacking a screening solution, potentially unlocking a $25 billion market.
Revenue ExpectationsManagement raised full-year 2025 revenue guidance by $55 million at the midpoint, reflecting strong future revenue expectations.
Bears Say
Competitive PositionEXAS is unlikely to launch Freenome's assay until it receives FDA approval, placing it at least 2 years behind competitor GH Shield.
Regulatory ChallengesMCED screening tests are not yet formally reimbursed, creating uncertainty in achieving full market penetration.
Trial PerformanceThe disappointing BLUE-C LBx results landed below the NCD requirement of 74% sensitivity, yielding a test that is very unlikely to have commercial potential.
Exact Sciences News
EXAS FAQ
What was Exact Sciences Corp.’s price range in the past 12 months?
Exact Sciences Corp. lowest stock price was $38.81 and its highest was $72.83 in the past 12 months.
What is Exact Sciences Corp.’s market cap?
Exact Sciences Corp.’s market cap is $11.88B.
When is Exact Sciences Corp.’s upcoming earnings report date?
Exact Sciences Corp.’s upcoming earnings report date is Nov 03, 2025 which is in 11 days.
How were Exact Sciences Corp.’s earnings last quarter?
Exact Sciences Corp. released its earnings results on Aug 06, 2025. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.126 by $0.116.
Is Exact Sciences Corp. overvalued?
According to Wall Street analysts Exact Sciences Corp.’s price is currently Undervalued.
Does Exact Sciences Corp. pay dividends?
Exact Sciences Corp. does not currently pay dividends.
What is Exact Sciences Corp.’s EPS estimate?
Exact Sciences Corp.’s EPS estimate is -0.04.
How many shares outstanding does Exact Sciences Corp. have?
Exact Sciences Corp. has 189,319,100 shares outstanding.
What happened to Exact Sciences Corp.’s price movement after its last earnings report?
Exact Sciences Corp. reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.126. Following the earnings report the stock price went down -7.994%.
Which hedge fund is a major shareholder of Exact Sciences Corp.?
Currently, no hedge funds are holding shares in EXAS
Exact Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.76 (7.71% Upside)
$67.76 (7.71% Upside)
Blogger Sentiment
Bullish
EXAS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 958.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 10.0%
Last 30 Days ▲ 10.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.73%
12-Months-Change
Fundamentals
Return on Equity
-35.51%
Trailing 12-Months
Asset Growth
-13.13%
Trailing 12-Months
Company Description
Exact Sciences Corp.
Exact Sciences Corporation is a molecular diagnostics company based in Madison, Wisconsin, primarily focused on the early detection and prevention of cancer. The company operates in the healthcare sector, specializing in non-invasive screening tests for colorectal and other cancers. Its flagship product, Cologuard, is a stool-based DNA test designed to detect colorectal cancer and precursors to the disease, while the company is also involved in developing tests for other types of cancers, enhancing its portfolio of oncology-focused diagnostic solutions.
EXAS Company Deck
EXAS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong operational and financial performance with record-breaking results and increased guidance. However, the disappointment from the blood-based test results and reliance on external technology for CRC blood screening pose challenges. Nonetheless, the expansion of Cologuard Plus and new product launches demonstrate robust growth potential.View all EXAS earnings summariesEXAS Revenue Breakdown
74.59% Screening
25.17% Precision Oncology
0.24% COVID-19 Testing
EXAS Stock 12 Month Forecast
Average Price Target
$67.76
▲(7.71% Upside)
Technical Analysis
Ownership Overview
1.05% Insiders
44.38% Mutual Funds
0.54% Other Institutional Investors
39.60% Public Companies and Individual Investors